

DIVI'S LABORATORIES LIMITED

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2008

(Rs.in Lakhs)

	Particulars	STAND ALONE		
		Unaudited	Unaudited	Audited
		Quarter ended 30.06.2008	Quarter Ended 30.06.2007	Year Ended 31.03.2008
	(1)	(2)	(3)	(4)
1	Net Sales/Income from operations (net of Excise Duty)	26607	22807	103319
2	Other Income	519	306	1361
3	<u>Total Income:</u>	27126	23113	104680
4	<u>Expenditure:</u>			
	a. (Increase) / Decrease in Stock	(2801)	(623)	(3219)
	b. Consumption of Raw Material	12245	10713	44388
	c. Purchase of Traded Goods	0	0	0
	d. Staff Cost	1482	1148	5054
	e. Depreciation	1073	861	3565
	f. Other Expenditure			
	- Manufacturing Expenses	1899	1416	6451
	- Other expenses	2801	1689	8954
	g. Total	16699	15204	65193
5	Finance charges	196	337	1018
6	Exceptional items	0	0	0
7	<u>Profit from ordinary activities before Tax: (3)-(4+5+6)</u>	10231	7572	38469
	Tax Expense			
8	- Current Tax	745	847	3834
	- MAT Credit Entitlements	(331)	(362)	(1930)
	- Deferred Tax	162	355	1177
	- Fringe Benefit Tax	7	4	32
9	<u>Net Profit from ordinary activities after Tax: (7-8)</u>	9648	6728	35356
10	Extra-ordinary items (net of tax expense)	0	0	0
11	Net Profit for the period (9-10)	9648	6728	35356
12	Paid-up Equity Share Capital (Face value of Rs.2/- each)	1293	1291	1291
13	Reserves excluding revaluation reserves			86107
14	Basic Earnings Per Share			
a)	Basic Earnings Per Share before extra-ordinary items Rs.	14.92	10.42	54.77
	Diluted Earnings Per Share before extra-ordinary items Rs.	14.76	10.37	54.14

b)	Basic Earnings Per Share after extra-ordinary items	Rs.	14.92	10.42	54.77
	Diluted Earnings Per Share after extra-ordinary items	Rs.	14.76	10.37	54.14
15	Public shareholding:				
	- No. of shares		30088450	29992600	29972600
	- % of shareholding		46.52%	46.46%	46.43%

NOTES:

1. The above results for the Quarter ended 30th June 2008, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 26th July, 2008.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 on Segment Reporting issued by the Institute of Chartered Accountants of India.
3. The financial results for the quarter ended 30th June 2008 have been subjected to limited review carried out by the statutory auditors of the company.
4. The figures for the previous year/period have been regrouped, wherever necessary.
5. Consolidated Financial Results of the company with its subsidiaries M/s.Divis Laboratories (USA) Inc and M/s.Divi's Laboratories Europe AG are given below:

		Rs.lakhs		
	Particulars	Quarter ended 30.06.2008	Quarter ended 30.06.2007	Year Ended 31.03.2008
1	Turnover	26358	22672	103283
2	Net Profit after tax	9433	6490	34760
3	Earnings Per Share (Face Value Rs.2 each)			
	Basic:	Rs. 14.59	10.05	53.84
	Diluted:	Rs. 14.43	10.00	53.23

6. Details of Investor complaints pursuant to Clause 41 of the Listing Agreement for the quarter ended 30.06.2008:

Opening: Nil, Received during the Quarter: 4, Resolved: 4, Closing: Nil

for Divi's Laboratories Limited

Place: Hyderabad
Date: 26th July, 2008

Dr. Murali K. Divi
Chairman & Managing Director